TARS

TARSUS PHARMACEUTICALS, INC.

TARS · CIK 1819790 · Annual (10-K) · Last 6 years

Financial Trends

Revenue$451M
20202025
Net Income−$66M
20202025
Operating CF−$12M
20202025
Free Cash Flow−$22M
20202025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Revenue$0.5B$0.2B$0.0B$0.0B$0.1B—
Cost of Revenue——————
Gross Profit——————
R&D Expense$0.1B$0.1B$0.1B$0.0B$0.0B$0.0B
SG&A Expense$0.4B$0.2B$0.1B———
Operating Income$-0.1B$-0.1B$-0.1B$-0.1B$-0.0B$-0.0B
Net Income$-0.1B$-0.1B$-0.1B$-0.1B$-0.0B$-0.0B
EPS (Basic)$-1.59$-3.07$-4.62$-2.52$-0.67—
EPS (Diluted)$-1.59$-3.07$-4.62$-2.52$-0.67—

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Total Assets$0.6B$0.4B$0.3B$0.2B$0.2B$0.2B
Current Assets$0.5B$0.4B$0.3B$0.2B$0.2B$0.2B
Cash & Equivalents$0.2B$0.1B$0.2B$0.1B$0.2B$0.2B
Total Liabilities$0.2B$0.2B$0.1B$0.0B$0.0B$0.0B
Current Liabilities$0.1B$0.1B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.3B$0.2B$0.2B$0.2B$0.2B$0.2B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Operating Cash Flow$-0.0B$-0.1B$-0.1B$-0.0B$0.0B$-0.0B
Investing Cash Flow$-0.0B$-0.2B$0.1B$-0.1B$-0.0B$-0.0B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.1B$0.2B$0.1B$0.1B$0.0B$0.1B
← Companies